^
Association details:
| Biomarker: | MAST4 mutation |
|---|---|
| Cancer: | Bladder Cancer |
| Regimen: | |
| Direction: | Resistant |
Evidence:
Source:
Title:
Biomarker Exploration for neoadjuvant chemotherapy with gemcitabine combined with cisplatin in muscle-invasive bladder cancer.
Published date:
05/26/2022
Excerpt:
A total of 23 patients were enrolled in this study, all of whom were cT2-T4aNxM0 MIBC and received 2̃4 cycles CG (gemcitabine and cisplatin) NCT....our results showed that 3 patients in the non-responder group had MAST4 gene mutations, but not in the responder group, and there was a significant difference between the two groups (p < 0.05).
DOI:
10.1200/JCO.2022.40.16_suppl.e16556